Q-omics provides the consensus-scored TGM1 profile across patient tissues and cancer cell-line models. TGM1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TGM1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TGM1 RNA expression shows 18,144 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where TGM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGM1 survival associations across molecular data types. TGM1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGM1 RNA expression–survival associations across cancer types. High TGM1 expression shows unfavorable associations in ACC, KIRC, KICH, LIHC and COAD, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TGM1 RNA expression.
This table summarizes TGM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TGM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGM1 shows lower tumor expression in HNSC, LUAD, KICH and KIRP and higher tumor expression in THCA and COAD. The HNSC box plot shows higher TGM1 RNA expression in normal versus tumor tissue (log2 FC = −2.199, t-test p = .002).
This table shows molecular features associated with TGM1 in patient tissues and cancer cell lines. In patient samples, TGM1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TGM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
